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Summary
Using directed in vitro protein evolution, we generated
proteins that bound and antagonized the function of
vascular endothelial growth factor receptor 2
(VEGFR2). Binders to human VEGFR2 (KDR) with 10–
200 nM affinities were selected by using mRNA display
from a library (1013 variants) based on the tenth human
fibronectin type III domain (10Fn3) scaffold. Subse-
quently, a single KDR binding clone (Kd = 11 nM) was
subjected to affinity maturation. This yielded im-
proved KDR binding molecules with affinities ranging
from 0.06 to 2 nM. Molecules with dual binding speci-
ficities (human/mouse) were also isolated by using
both KDR and Flk-1 (mouse VEGFR2) as targets in se-
lection. Proteins encoded by the selected clones
bound VEGFR2-expressing cells and inhibited their
VEGF-dependent proliferation. Our results demon-
strate the potential of these inhibitors in the develop-
ment of anti-angiogenesis therapeutics.
Introduction
Directed protein evolution has shown promise in har-
nessing desired changes in the properties and function-
alities of proteins. Several techniques that couple pro-
teins to their coding information have made it possible
to carry out directed protein evolution by in vitro selec-
tion [1–3], and this allows for the rapid identification of
desired molecules from libraries with large numbers of
variants. Folded polypeptide frameworks provide useful
scaffolds for presenting amino acid variability in a pro-
tein library [4]. From a therapeutic perspective, the opti-
mal binding protein should be of human origin to mini-
mize immunogenicity, it should be sufficiently stable to
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chusetts 01702.be expressed in a microbial system at high levels, and
it should be adaptable so as to accommodate the
changes needed to allow specific target binding and bi-
ological functionality. The tenth human fibronectin type
III domain (10Fn3), a stable, small protein (10 kD, Tm >
80ºC) with a folded structure similar to the variable do-
mains of antibodies, has been exploited to develop
binding molecules to a diverse array of targets [5–8].
However, to date, no biological activities have been
reported for any binding molecule derived from this
scaffold.
In this study, we exploited the 10Fn3 scaffold to target
vascular endothelial growth factor receptor 2 (VEGFR2).
VEGF and two of its receptors, VEGFR1 (fms-like tyro-
sine kinase1, Flt-1) and VEGFR2 (kinase insert domain
receptor, KDR), are major regulators of endothelial cell
activities, including vasculogenesis and angiogenesis
[9]. Angiogenesis, the formation of new blood vessels
from preexisting vasculature, occurs under both normal
and pathologic conditions. VEGFR2 activation plays
a major role in pathological angiogenesis [10] and has
been targeted for cancer therapeutic intervention. A
number of inhibitors of angiogenesis have been identi-
fied, including naturally occurring factors such as an-
giostatin and endostatin [11], engineered natural bio-
logics such as VEGF-trap [12], and synthetic small
molecules, peptides, oligonucleotides, and antibodies
[13]. Many such inhibitors have shown promising neu-
tralizing activities in biological assays and animal model
studies, and some have demonstrated medical benefit
in controlled clinical studies. For example, the anti-
VEGF antibody Avastin (Bevacizumab) [14] has been
shown to be beneficial to patients suffering from late
stages of colon, non-small-cell lung, and breast cancers.
Here, we report the first example of engineered biologi-
cal inhibitors to VEGFR2 discovered by altering a natural
human protein domain through molecular evolution by
mRNA display, an in vitro display technology that allows
a covalent linkage of a protein and its coding mRNA [15,
16]. The identification of this new class of binding mole-
cules demonstrates the potential of this engineered
scaffold in generating novel therapeutic proteins.
Results and Discussion
Initial Identification of KDR Binding Molecules
A 10Fn3 mRNA fusion library (1013 variants) was used in
in vitro selection against the extracellular domain of hu-
man VEGFR2. After 6 rounds of selection, 30 indepen-
dent clones were tested for binding to KDR, and the
best binders were subsequently tested for binding in
the presence of VEGF (Figure 1A). VEGF inhibited target
binding of multiple clones, suggesting that these
binders may interfere with the natural VEGF-KDR inter-
action. Indeed, in a BIAcore assay, binders VR28 and
VR12, but not a noncompeting clone (VR17), inhibited
KDR binding to immobilized VEGF in a dose-dependent
manner (Figure 1B). VR28 protein also bound KDR-
expressing recombinant CHO cells, but not control CHO
cells (Figure 1C). VR28 had the best affinity to KDR
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550(11–13 nM) among the tested clones, but it showed little
inhibition of VEGF-KDR signaling in a VEGF-dependent
cell proliferation assay (IC50 > 200 nM, data not shown).
Thus, while the initial selection from the naı¨ve library
yielded multiple binding molecules that interfered with
the interaction between VEGF and KDR in biochemical
binding studies, affinity improvements appeared to be
necessary for neutralizing KDR function in a biological
assay, perhaps due to the high-affinity interaction be-
tween VEGF and KDR (75–125 pM) [17]. VR28 was cho-
sen for affinity maturation since it had the best binding
affinity to KDR, had the ability to inhibit VEGF and KDR
Figure 1. Characterization of Clones Isolated from Initial KDR Se-
lection
(A) VEGF inhibits interaction between KDR and selected binding
molecules. A radioactive equilibrium binding assay was performed
with clones from Round 6 (0.1 pmol) with KDR-Fc (2.5 pmol) in the
presence or absence of VEGF (10 pmol). Binding was expressed as
a percentage of input binder material. Nonspecific binding to the
beads in the absence of KDR-Fc represented less than 2%.
(B) Recombinant binder proteins disrupt the VEGF and KDR inter-
action. Binding of KDR-Fc (2.5 pmol) to immobilized VEGF (2.5
pmol) in the presence of different concentrations of VR28, VR12,
and VR17 was evaluated in a BIAcore binding assay. RU detected
by KDR-Fc binding in the absence of competitor was assigned as
100%.
(C) VR28 binding to KDR-expressing CHO (KDR) and control CHO
cells was detected by an immunofluorescent sandwich assay by
using fluorescent microscopy.interaction in binding studies in vitro, and lacked muta-
tions in the framework regions.
Affinity Maturation of the VR28 Clone
The sequence of the binding loops of VR28 is shown in
Table 1. We initially constructed libraries by introducing
mutations to all three loops of VR28 by using hypermu-
tagenic PCR. Selection against KDR from these libraries
yielded binding molecules with moderate affinity im-
provement (a Kd as low as 1 nM, data not shown). Al-
though many beneficial mutations were selected in the
FG loop (for example, V77M, Q79R, N80S, D81G,
H82R, and I85F), mutations in the BC and DE loops ap-
peared to be random and didn’t further improve affinity
to KDR. Furthermore, reverse selection to VR28 BC and
DE loop amino acids was evident, as indicated by differ-
ent codon usages in selected clones. Overall, despite
a similar average mutation rate of the three loop regions
prior to selection (BC = 28.6%, DE = 31.6%, FG = 22.3%),
the FG loop of selected clones (n = 100) revealed ap-
proximately 5-fold more mutations than the BC and DE
loops (19.3%, 3.5%, and 4.2%, respectively), suggest-
ing a greater potential to target the FG loop sequence
for additional affinity improvements.
Two incidental mutations in the N-terminal region, L8P
and L8Q, also resulted in better binding to KDR in a num-
ber of selected clones. Several residues in the N termi-
nus of the 10Fn3 domain are located in close proximity
to the FG loop based on structure studies [18]. This
could potentially have a negative impact on target
binding. A location change of the N terminus relative to
the FG loop, perhaps as a result of Leu8 mutations,
could presumably improve KDR binding affinity. Indeed,
deletion of the first eight amino acids from the N termi-
nus of these clones improved binding to KDR (data not
shown).
Consequently, new libraries (with or without the N-ter-
minal deletion) were constructed to introduce mutations
Table 1. VEGFR2 Binding Clones
Clone
BC Loop
(23–29)
DE Loop
(52–55)
FG Loop
(77–86), P87
WT DAPAVTV GSKS GRGDSPASSKP
VR28 RHPHFPT LQPP VAQNDHELITP
K1 RHPHFPT LQPP MGLYGHELLTP
K6 RHPHFPT LQPP DGKDGRVLLTP
K9 RHPHFPT LQPP FGLYGKELLIP
K10 RHPHFPT LQPP TGPNDRLLFVP
K12 RHPHFPT LQPP DVYNDHEIKTP
K13 RHPHFPT LQPP LALKGHELLTP
K14 RHPHFPT LQPP REENDHELLIP
K15 RHPHFPT LQPP EVHHDREIKTP
E3 RHPHFPT LQPP DGRNDRKLMVP
E5 RHPHFPT LQPP DGQNGRLLNVP
E6 RHPHFPT LQPP DGWNGRLLSIP
E9 RHPHFPT LQPP EERNGRTLRTP
E18 RHPHFPT LQPP VERNGRELNTP
E19 RHPHFPT LQPP VERNGRHLMTP
E25 RHPHFPT LQPP LERNGRELMTP
E26 RHPHFPT LQPP VERNGRELMTP
E28 RHPHFPT LQPP LERNGRELMVP
E29 RHPHFPT LQPP VERNGRVLMTP
The FG loop residues in bold indicate residues different from the
parental clone VR28.
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551to the FG loop of VR28 by using oligonucleotide-derived
mutagenesis, which resulted in more than six amino acid
changes per FG loop. Lower KDR concentrations were
utilized during selection to favor clones with better affin-
ities. The N-terminal deletion yielded higher KDR bind-
ing activity than the nondeleted population. Target bind-
ing of selection populations and clones from Round 4 is
shown in Figure 2. The affinity binding constants of indi-
vidual clones to KDR ranged from 0.32 to 1.8 nM, a 10- to
30-fold improvement over VR28 (11 nM) (Figure 3A). The
binding activity appeared to be specific to KDR rather
than to the Fc portion since several tested clones didn’t
bind to high concentrations of IgG-Fc (data not shown);
this finding indicated that the negative selec-
tion (preclear) against IgG was effective in suppressing
Fc binders.
Sequence analysis of the selected clones from affinity
maturation through oligo-based mutagenesis revealed
that while the binding population was diverse, several
consensus motifs were present (Table 1, K clones).
Figure 2. Affinity Maturation of VR28
Binding was measured in a radioactive equilibrium assay.
(A) VR28, starting pool, and selected populations to 1 nM KDR-Fc
or Flk-1-Fc.
(B) Clones from Round 4 (K clones) and Round 7 (E clones) to 1 nM
KDR-Fc and Flk-1-Fc. The data represent an average of three inde-
pendent experiments.
(C) Clones from Round 7 (E clones) to 100 nM KDR-Fc, Flk-1-Fc, or
Flt-1-Fc.Most noticeably, as in VR28, Pro87 and Leu84 were
found in nearly all clones, suggesting that these residues
may be essential for the binding site. A positively
charged amino acid at position 82 appears to be re-
quired, since only H82K or H82R changes were seen in
the sequenced clones. Aliphatic amino acid was pre-
dominant at position 78. D81 was often mutated to
a G, resulting in the loss of negative charge at this posi-
tion and a potential gain in flexibility. The overall muta-
tion rate in the selected population was comparable to
the pool prior to selection, suggesting that the FG loop
is very tolerant to structural changes. To further verify
the impact of the N terminus on target binding, we cre-
ated variants with and without the N terminus deletion
of 23 clones from Round 4. Binding to KDR was
Figure 3. Affinity Maturation Yielded KDR Binding Proteins with Im-
proved Binding Affinity
(A) Binding affinities to KDR as measured in a radioactive equilib-
rium binding assay for VR28 (-; Kd = 11 6 0.5 nM) and selected
clones from Round 4: K1 (:; Kd = 0.6 6 0.1), K6 (;; Kd = 0.9 6
0.1), K9 (A; Kd = 1.8 6 0.4), K10 (d; Kd = 0.6 6 0.1), K12 (,;
Kd = 0.6 6 0.1), K13 (6; Kd = 0.6 6 0.1), K14 (7; Kd = 0.6 6 0.1),
and K15 (>; Kd = 0.4 6 0.1).
(B) N terminus deletion improved binding to KDR. The data repre-
sent an average binding to 1 nM KDR of 23 independent clones
with and without deletion of the first 8 amino acid residues in the
N terminus.
(C) Two arginine residues are important for binding to Flk-1. When
the arginine at position 79 or position 82 was replaced by other
amino acids (X79 = E, Q, W, P; X82 = L, K), binding to Flk-1, but
not to KDR, decreased significantly. Clones from Round 7 of affinity
maturation selection were analyzed for binding to 1 nM KDR and
Flk-1 in a radioactive equilibrium binding assay. The data represent
an average binding of four (R79), seven (X79), three (R82), and four
(X82) independent clones from Round 7.
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clone showed no change in binding. On average, the de-
letion resulted in an w3-fold improvement in binding
(Figure 3B).
Selection of Binders with Dual Specificities
to Human and Mouse VEGFR2
VR28 and most of the affinity-matured variants (K
clones) failed to bind Flk-1, as shown in Figure 2B. How-
ever, since KDR and Flk-1 share a high level (85%) of se-
quence identity, and since both can be activated by hu-
man VEGF [19, 20], it is conceivable that novel variants
can be evolved to bind both KDR and Flk-1, presumably
by recognizing similar residues or structures shared by
KDR and Flk-1. This will allow the same molecule to be
tested in functional studies in animal models and, sub-
sequently, in humans.
Therefore, the population that had been selected for
four rounds against KDR was further selected against
Flk-1. As shown in Figure 2, an increase in binding to
Flk-1 was observed from Round 5 to Round 7, indicating
enrichment of Flk-1 binders. In contrast to the clones se-
lected against KDR only (K clones), most clones derived
from additional selection against Flk-1 (E clones) are
able to interact with both KDR and Flk-1 (Figure 2B).
The binding analysis, shown in Table 2, indicates that
the clones were able to bind both targets with high affin-
ities. For example, E19 has a Kd of 56 pM to KDR and
a Kd of 340 pM to Flk-1. The target switch strategy has
allowed for the isolation of molecules with dual binding
specificities to both KDR and Flk-1 from a mutagenized
population of VR28, a moderate KDR binder that was not
able to bind Flk-1. The selected binders are highly spe-
cific to VEGFR2, as no substantial binding to VEGFR1,
which shares 31% sequence identity to VEGFR2 in its
extracellular domain [21], was observed at a high target
concentration (Figure 2C). Specific binding to KDR
would be desirable for a therapeutic candidate to reduce
the risk of side effects.
Sequence analysis (Table 1) revealed some motifs
similar to those observed in the KDR binder pool (Leu
and Pro at residues 84 and 87, respectively; positively
charged amino acid at residue 82 [predominantly Arg])
and some that were not maintained (aliphatic at position
78). In addition, while the motif ERNGR (residues 78–82)
was present in almost all clones binding to Flk-1, it was
rarely found in the populations selected on KDR only.
R79 and R82 appear to be particularly important for
high-affinity binding to Flk-1, since binding to Flk-1,
but not KDR, is greatly reduced when a different residue
is present at this position (Figure 3C).
To determine whether all three loops are required for
target binding, the loop sequences of clones E6 and
E26 were substituted one at a time by a randomized se-
quence of corresponding length encoded by NNS. The
resulting populations were expressed by in vitro transla-
tion and were purified by a C-terminal FLAG tag. There-
fore, the purified proteins should be devoid of se-
quences containing frameshifts and stop codons.
Proteins derived from each loop replacement failed to
bind the target (data not shown). This result suggests
that any combination of just two nonrandomized loops
may not be sufficient for target binding. A second possi-
bility is that a large portion of the randomized loop se-quences was incompatible with the rest of the domain,
resulting in unfolded proteins. In the context of VR28,
point mutations of P25 or F27 in the BC loop and L52,
Q53, or P54 in the DE loop eliminated binding to KDR
(data not shown). In addition, when a loop of another
KDR binder was replaced by the analogous wild-type
10Fn3 loop, target binding was abolished [22]. Together,
these results suggest that the selected loop sequences
are involved in binding in a coordinated fashion, and that
each one plays a role in interacting with the target and/or
in maintaining the properly folded structure of the pro-
tein. The requirement of all three loops also suggests
that the randomization strategy allowed 10Fn3 to main-
tain a folded structure for proper display of varied se-
quences in the three loop segments.
Selected Binders Interact with Cell Surface-
Expressed VEGFR2 and Neutralize Its Function
The ultimate therapeutic utility of the selected KDR bind-
ing molecules will depend heavily on their functionality
after recombinant production. We expressed a number
of the binding molecules in an E. coli expression system
and purified them from soluble fraction by affinity chro-
matography via a His6 tag. The expression level and sol-
ubility varied between binders; however, in many cases,
we were able to purify 20–40 mg protein/l culture from
the soluble fraction. The stability of the binders derived
from 10Fn3 differed from binder to binder [22], and Tm
values ranged from 37ºC to 65ºC (data not shown).
Using a detection system consisting of a primary
mouse anti-His6 tag antibody followed by a fluorescently
labeled secondary antibody, the recombinant binding
molecules were shown to bind specifically to mamma-
lian cells expressing KDR or Flk-1 with low nanomolar
IC50, while no binding was observed for wild-type
10Fn3 (Figure 4). Furthermore, many selected clones in-
hibited VEGF-stimulated cell proliferation in a dose-de-
pendent fashion, with IC50s as low as 3–12 nM for
KDR-expressing cells and 2–5 nM for Flk-1-expressing
cells. The potency of inhibition appeared to be similar
to that of the control anti-KDR and anti-Flk-1 monoclo-
nal antibodies, as shown in Figure 5.
A number of clones were further tested for inhibitory
activity against HUVEC cells that require VEGF for prolif-
eration. As shown in Figure 5C, the KDR binding mole-
cules were also active in antagonizing VEGF activity in
this human cell system; though, the wild-type 10Fn3
Table 2. Affinity of Selected Binders
Clone Target
In Vitro
Kd (nM)
Ka
(1/M*s) 3 105
Kd
(1/s) 3 1025
BIAcore
Kd (nM)
E6 KDR 0.4 6 0.1 8.9 6.7 0.08
Flk-1 7.1 6 1.1 6.7 136.0 2.02
E18 KDR 1.2 6 0.2 2.6 12.1 0.46
Flk-1 0.5 6 0.1 6.0 19.5 0.33
E19 KDR 1.3 6 0.2 3.0 1.7 0.06
Flk-1 0.7 6 0.1 6.6 22.3 0.34
E25 KDR 1.6 6 0.4 2.5 5.2 0.21
Flk-1 1.3 6 0.2 5.0 37.8 0.76
E26 KDR 1.7 6 0.4 1.1 5.8 0.51
Flk-1 2.0 6 0.3 2.2 47.7 2.14
E29 KDR 1.5 6 0.4 3.6 7.0 0.19
Flk-1 0.9 6 0.2 7.9 28.8 0.37
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nM, a concentration approaching utility for biotherapeu-
tic candidates.
The improved binding affinity of KDR binders resulted
in their ability to inhibit VEGF-dependent cell prolifera-
tion with low nanomolar IC50, suggesting a direct corre-
lation between affinities and neutralizing activity. Since
the binding population was diverse, it is possible that
still more potent inhibitors may exist in this population;
however, they were not identified due to our limited sam-
pling size of individual clones. Additional stringent se-
lection may allow for the identification of those clones.
Significance
Interaction between vascular endothelial growth fac-
tor (VEGF) and its receptors plays a central role in an-
giogenesis. Antagonists that disrupt this interaction
are shown to have clinical utility in the treatment of
neoplastic diseases and retinal angiopathies. We re-
port here the identification of a class of engineered
proteins capable of inhibiting VEGFR2. Using mRNA
display and directed protein evolution, we sampled a li-
brary based on the tenth human fibronectin type III do-
main and identified molecules with nanomolar affinity
to human VEGFR2. Upon affinity maturation of a pro-
genitor clone (Kd = 11 nM), descendant binding mole-
cules bound the target with subnanomolar affinity
(as low as 60 pM) and disrupted the function of
VEGFR2 in a number of cell types with a low nanomo-
lar IC50 comparable to that observed for a high-affinity
anti-KDR antibody [23]. These relatively small proteins
(10 kD) can offer advantages in situations (such as tis-
sue penetration and manufacturing) where larger pro-
Figure 4. Affinity-Matured Proteins Specifically Bind to VEGFR2-
Expressing Cells
(A) Binding of E18 (-; IC50 = 4.2 6 1.0), E19 (:; IC50 = 7.6 6 1.7),
E26 (;; IC50 = 2.6 6 1.2), E29 (A; IC50 = 2.3 6 1.0), and WT (,;
n.d.) to CHO-KDR cells expressing human KDR.
(B) Binding of E18 (-; IC50 = 0.9 6 0.4), E19 (:; IC50 = 5.3 6 2.5),
E26 (;; IC50 = 1.3 6 0.7), E29 (A; IC50 = 0.6 6 0.1), and WT (,;
n.d.) to CHO-Flk-1 cells expressing Epo-Flk-1 chimera. No binding
was detected to control CHO cells (data not shown).tein therapeutics (such as antibodies) are limited.
Using a novel mutagenesis and selection strategy,
we identified binding molecules to both human and
mouse VEGFR2 by targeted randomization of a KDR
binder that originally did not bind Flk-1. This makes
it possible for the same molecules to be used in studies
in mouse and human subjects, allowing for the avoid-
ance of pitfalls that may be associated with a molecule
switch between these studies. Our work demonstrates
for the first time that these VEGFR2 antagonists have
the potential to be developed as therapeutics to inhibit
pathologic angiogenesis.
Experimental Procedures
Recombinant Proteins
Human and murine VEGF, human neurotrophin-4 (NT4), and human
and mouse VEGFR2 Fc (KDR-Fc and Flk-1-Fc) were purchased from
R&D Systems (Minneapolis, MN).
Figure 5. Affinity-Matured Binding Proteins Antagonize VEGFR2
Function
(A–C) E. coli-produced VEGFR2 binding proteins and control anti-
VEGFR2 antibodies were tested for inhibition to VEGF-dependent
cell proliferation as measured by absorbance at 490 nm using
Cell Titer 96. (A) KDR-expressing cells (Ba/F3-KDR): E18 (-; IC50 =
5.4 6 1.2 nM), E19 (:; IC50 = 12.3 6 2.6), E26 (;; IC50 = 3.2 6 0.5),
E29 (A; IC50 = 10.0 6 2.1), WT (,; n.d.), and anti-KDR antibody
(6; IC50 = 17.3 6 7.7); (B) Flk-1-expressing cells (Ba/F3-Flk-1): E18
(-; IC50 = 2.4 6 0.2), E19 (:; IC50 = 5.8 6 1.0), E26 (;; IC50 = 5.3 6
1.7), E29 (A; IC50 = 4.7 6 1.2), WT (,; n.d.), and anti-Flk-1 antibody
(6; IC50 = 15.06 3.2); and (C) human umbilical vein endothelial cells
(HUVEC): E18 (-; IC50 = 12.8 6 4.6), E19 (:; IC50 = 11.8 6 2.7), E26
(;; IC50 = 14.0 6 5.9), E29 (A; IC50 = 8.4 6 0.8), and WT (,; n.d.).
The data represent an average of two independent experiments.
No inhibition was observed for control cells (Ba/F3-TrkB) that re-
quired NT4 for proliferation (data not shown).
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The construction of the library with 10Fn3 as a scaffold was previ-
ously described [6]. Three loop regions, BC, DE, and FG, corre-
sponding to positions 23–29, 52–55, and 77–86, respectively, were
randomized by using NNS as the coding scheme. This library con-
tained w1 3 1013 members and was used in the KDR selection
that identified the initial KDR binding clones, including VR28.
Mutagenic Library Construction
Hypermutagenic PCR
An incidental scaffold mutation, T69I, in VR28 was corrected by PCR
with no change in its binding activity to KDR (data not shown). Using
hypermutagenic PCR (1 mM dGTP, 0.03 mM dCTP, 1 mM dTTP, 0.03
mM dATP, 0.5 mM Mn2+) [24] with loop flanking primers, we intro-
duced mutations to each of the three loops of VR28. One, two, or
three rounds of PCR were conducted separately on each of the three
loops. The resulting fragments from each round of mutagenesis were
combined, and the libraries were assembled by using overlap exten-
sion and PCR. A total of 10–15 clones from each round of mutagene-
sis were analyzed by sequencing, and the mutagenesis rate was
found to be similar to published results [24]. On average, each round
of mutagenic PCR resulted in 10% amino acid mutations in all three
loops (18% for one round, 27% for two rounds, and 33% for three
rounds). We observed 1.5% framework mutations after three rounds,
a value significantly lower than that of the targeted loop regions
(33%). Mutagenized libraries showed significantly reduced binding
to KDR: 5.6%, 1.6%, and 1.0% binding to 25 nM KDR for libraries
from one, two, and three rounds, respectively, as compared to 24%
for VR28 (data not shown). The three libraries were combined at equal
molar ratio and were subjected to selection against 1 nM KDR.
Oligo-Based Mutagenesis
The FG loop (residues 77–86; VAQNDHELIT) and position Pro87 of
VR28 were mutagenized by oligonucleotide VR28FG-50, containing
50% of the VR28 nucleotide and 50% of N or S at each position, which
resulted in w67% random amino acid changes in the FG loop and
Pro87. The sequence of VR28FG-50 was 50-gtg tat gct gtc act g/n t/n
g/s g/n c/n c/s c/n a/n g/s a/n a/n c/s g/n a/n c/s c/n a/n c/s g/n a/n g/s
c/n t/n c/s a/n t/n c/s a/n c/n c/s c/n c/n a/s att tcc att aat tac-30. The
mutagenized library was assembled by PCR. DNA sequencing of
library members confirmed the intended mutation rate.
Mutagenesis of Flk-1 binding clones (E clones) was conducted
with primers with NNS at all loop positions, resulting in fully random-
ized BC, DE, or FG loops. Deletion of the N-terminal eight amino acid
residues was carried out by using standard PCR techniques. All con-
structs and mutagenic libraries contained T7 TMV promoter and Flag
tag sequences at the 50 and 30 flanking regions, respectively, for pro-
duction and purification of mRNA fusion molecules and proteins.
mRNA Fusion Production
For each round of selection, DNA from PCR was transcribed by us-
ing the MegaScript transcription kit (Ambion). The puromycin-con-
taining linker TEG 6/10 was synthesized and crosslinked to RNA
as previously described [25]. The crosslinked mixture was included
in an in vitro translation reaction by using the rabbit reticulocyte ly-
sate translation kit (Ambion) in the presence of 35S-labeled methio-
nine at 30ºC for 60 min. To enhance the fusion formation, 0.5 M
KCl and 0.05 M MgCl2 were added to the reaction and incubated
for 30 min at 4ºC. Fusion molecules were purified by using oligo-
dT cellulose chromatography. A reverse transcription reaction was
conducted with SuperScript II (Invitrogen) for 1 hr at 42ºC with the
primer Hu30FLAGSTOP (50-ttttaaatagcggatgccttgtcgtcgtcgtccttg-
tagtctgttcggtaattaatgg-30). Reactive cysteine residues were modi-
fied for 1 hr at room temperature with 1 mM 2-nitro-5-thiocyanato-
benzoic acid or N-ethylmaleimide at alternative rounds for the first
four rounds of selection. Fusion molecules were further purified by
anti-FLAG affinity chromatography by using M2 agarose (Sigma).
The fusion yield was calculated based on specific activity measured
by scintillation counting of 35S-methionine in the samples.
Selection
Primary Selection against KDR
A fusion library (w1013 variants in 1 ml) was incubated with 100 ml
Protein A beads (Dynal) prebound to human IgG for 1 hr at 30ºC prior
to selection (preclear). The supernatant was then incubated in bufferA (50 mM HEPES, 150 mM NaCl, 0.02% Triton X-100, 1 mg/ml bovine
serum albumin [BSA], 0.1 mg/ml salmon sperm DNA [pH 7.4]) with
KDR-Fc for 1 hr at 30ºC. The target was captured on 300 ml (round
1) or 100ml (rounds 2–6) Protein A beads for 30 min at 30ºC, and beads
were washed five times with 1 ml buffer A without BSA and salmon
sperm DNA. Bound fusion molecules were eluted with 100 ml 0.1 M
KOH into 50 ml 1 M Tris-HCl (pH 8.0). DNA was amplified by PCR
by using flanking primers. Final concentrations of KDR-Fc were
250 nM (round 1), 100 nM (rounds 2–4), and 10 nM (rounds 5 and 6).
Affinity and Specificity Maturation of KDR Binder VR28
mRNA fusion libraries of mutagenized VR28 were produced as de-
scribed above. Following preclear with Protein A beads prebound
to human IgG, selection was performed in buffer B (13 PBS,
0.02% Triton X-100, 1 mg/ml BSA, 0.1 mg/ml salmon sperm DNA
[pH 7.4]) for five rounds at 1 nM KDR. Libraries derived from oligo-
based mutagenesis were selected for four rounds at 0.1 nM KDR
and three additional rounds at 1 nM mouse VEGFR2 (Flk-1). Selec-
tions were stopped when no further increase in binding to the target
was observed.
Radioactive Equilibrium Binding Assay
35S-labeled binder proteins were produced in a rabbit reticulocyte
lysate translation kit (Ambion) and purified on M2-agarose (Sigma).
Varying concentrations of VEGFR2-Fc (0–200 nM) or VEGFR1-Fc
(1–100 nM) were incubated with a constant concentration of the pu-
rified binder protein (0.2 or 0.5 nM) at 30ºC for 30 min in buffer C (13
PBS, 0.02% Triton X-100 [pH 7.4]). The receptor-binder complexes
were captured by using Protein A magnetic beads for 10 min at
room temperature on a Kingfisher. The beads were washed six times
with 100 ml buffer C, and the protein was eluted with 100 ml 0.1 M
KOH. Samples were dried onto a LumaPlate-96 (Packard), and the
amount of 35S on the plate was measured with a TopCount NXT in-
strument (Packard). Data were analyzed by using the GraphPad
Prizm software (GraphPad Software, Inc., San Diego, CA), fitted
with a one-site, nonlinear binding equation.
Expression and Purification of Binder Proteins in E. coli
Binder proteins were expressed by using a pET9d vector in E. coli
BL21 (DE3) pLysS cells (Invitrogen). After induction and expression,
cell pellets were collected and resuspended in 50 ml lysis buffer D
(50 mM NaH2PO4 [pH 8.0], 0.5 M NaCl, 5% glycerol, 5 mM CHAPS,
25 mM imidazole, 13 Complete Protease Inhibitor Cocktail [Roche])
and sonicated on ice. The soluble fraction was separated by centri-
fugation, and the supernatant was rotated for 1 hr at 4ºC with 10 ml
TALON Superflow Metal Affinity Resin (Clontech) preequilibrated
with buffer E (50 mM NaH2PO4, 0.5 M NaCl, 5% glycerol, 25 mM im-
idazole [pH 8.0]). The resin was washed with 10 column volumes of
buffer E and 30 column volumes of buffer F (13 PBS [pH 7.4], 25 mM
imidazole [pH 7.4]). Protein was eluted with 13 PBS, 250 mM imid-
azole (pH 7.4) and was dialyzed against 13 PBS at 4ºC.
BIAcore Analysis
Using a BIAcore 2000, human and mouse VEGFR2-Fc were immobi-
lized onto a CM5 sensor chip, and binding proteins (0–100 nM) were
injected in buffer G (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20
[pH 7.4]). Rate constants, kon and koff, and the affinity constant, Kd,
were calculated by using BIA Evaluation 2.0 (BIAcore).
For inhibition experiments, human VEGF165 was immobilized on
a CM5 chip, and KDR-Fc (20 nM) was injected in the presence of
binding proteins (0–100 nM). IC50 represented the binder concentra-
tion at which 50% reduction of KDR binding to VEGF was observed.
Construction of Stable Cell Lines
DNA encoding chimeric receptors composed of the transmembrane
and cytoplasmic domains of the human erythropoietin receptor
(EpoR, amino acids 251–508) fused to the extracellular domains of
KDR (amino acids 1–764), Flk-1 (amino acids 1–762), or human
TrkB receptor (amino acids 1–430) were constructed by overlapping
PCR and were cloned into the EcoRI and XhoI sites of pcDNA 3.1(+)
(Invitrogen) to generate the plasmids phKE8 (KDR/EpoR fusion),
pmKE2 (Flk-1/EpoR fusion), and phTE (TrkB/EpoR fusion).
Construction of Cell Lines for Flow Cytometry
CHO-K1 cells (ATCC, Manassas, VA) were stably transfected by
using Lipofectamine 2000 (Invitrogen) with either pcDNA 3.1
Antagonists to Human and Mouse VEGF Receptor 2
555(Invitrogen), pmKE2, or a mixture of pcDNA 3.1 and a plasmid en-
coding full-length human KDR (Origene Inc., clone PR1371-H11).
Stable transfectants were selected and maintained in the presence
of 0.5 mg/ml Geneticin (Invitrogen). The human KDR-expressing
clone (CHO-KDR) and the murine Flk-1/EpoR chimera-expressing
population (CHO-Flk-1) were obtained by fluorescence-activated
cell sorting of the transfected population after staining with an
anti-KDR polyclonal antiserum (R&D Systems). CHO-KDR and
CHO-Flk-1 cell lines were grown routinely in Dulbecco’s modified
Eagle’s medium (DMEM; GIBCO-BRL) supplemented with 10%
(v/v) fetal bovine serum (FBS), 0.5 mg/ml Geneticin, 100 U/ml penicil-
lin, 0.25 mg/ml amphotericin B, 100 mg/ml streptomycin, and 2 mM
L-glutamine.
Construction of Ba/F3 Cell Lines
Cell lines that would proliferate in response to VEGF were con-
structed by transfection of the murine pre-B cell line Ba/F3 (DSMZ,
Braunschweig, Germany) with phKE8, pmKE2, and phTE. Ba/F3
cells were maintained in minimal Ba/F3 medium (RPMI-1640,
GIBCO-BRL) containing 10% FBS, 100 U/ml penicillin, 0.25 mg/ml
amphotericin B, 100 mg/ml streptomycin, and 2 mM L-glutamine
supplemented with 10% conditioned medium from WEHI-3B cells
(DSMZ; grown in Iscove’s modified Dulbecco’s medium [GIBCO-
BRL]/10% FBS/25 mM b-mercaptoethanol) as a source of essential
growth factors. After electroporation, stable transfectants were se-
lected in 0.75 mg/ml Geneticin and were maintained in the presence
of 100 ng/ml human VEGF165 (Ba/F3-KDR and Ba/F3-Flk-1 popula-
tions) or human NT4 (Ba/F3-TrkB).
Cell Surface Binding
Cell surface KDR and Flk-1 binding was analyzed simultaneously on
VEGFR2-expressing and control cells by flow cytometry. CHO-
pcDNA3 cells (control) were released from their dishes with tryp-
sin-EDTA, washed in Dulbecco’s PBS without calcium and magne-
sium (D-PBS2; Invitrogen), and stained for 30 min at 37ºC with 1.5
mM CMTMR (5-(and-6)-(4-chloromethyl)benzoyl)amino)-tetrame-
thylrhodamine) (Molecular Probes). The cells were washed in D-
PBS2, incubated for an additional 30 min at 37ºC, and then resus-
pended in blocking buffer (D-PBS2/10% fetal bovine serum) on
ice. CHO-KDR or CHO-Flk-1 cells were treated identically, except
that CMTMR was omitted. A total of 75,000 of CMTMR-stained
CHO-pcDNA3 cells were mixed with an equal number of unstained
CHO-KDR or CHO-Flk-1 cells in each well of a V-bottom 96-well
plate. All antibodies and binding proteins were diluted in 25 ml/well
blocking buffer, and each treatment was conducted for 1 hr at
4ºC. Cell mixtures were stained with His6-tagged binding proteins,
washed twice with cold D-PBS2, and then treated with 2.5 mg/ml
anti-His6 MAb (R&D Systems), washed, and stained with 4 mg/ml
Alexa Fluor 488-conjugated anti-mouse antibody (Molecular
Probes). For cells treated with an anti-KDR mouse monoclonal anti-
body (Accurate Chemical, Westbury, NY) or an anti-Flk-1 goat poly-
clonal antibody (R&D Systems), the anti-His6 step was omitted, and
antibody binding was detected with the species-appropriate Alexa
Fluor 488-conjugated secondary antibody (Molecular Probes). After
staining, cells were resuspended in 200 ml/well D-PBS2/1% FBS/1
mg/ml 7-aminoactinomycin D (7-AAD; Molecular Probes) and ana-
lyzed by flow cytometry on a FACSCalibur (Becton Dickinson, San
Jose, CA) equipped with a 488 nM laser. After gating to exclude
dead cells (7-AAD-positive), VEGFR2-expressing cells and CHO-
pcDNA3 cells were measured independently for Alexa Fluor 488
fluorescence by gating on the CMTMR-negative or -positive popula-
tions, respectively. Control experiments showed that staining with
CMTMR did not interfere with the detection of Alexa Fluor 488-con-
jugated antibodies on the surface of the stained cells (data not
shown).
Cell surface binding was also assessed by fluorescence micros-
copy with the secondary antibodies described above. For these
studies, antibodies were diluted in D-PBS containing calcium and
magnesium (D-PBS+)/10% FBS. Cells were grown on 24- or 96-
well plates, and, after staining, they were kept in D-PBS+ for obser-
vation on an inverted fluorescence microscope.
Cell Proliferation Assay
Ba/F3 cells were washed three times in minimal Ba/F3 medium and
were resuspended in the same medium containing 15.8 ng/ml hu-man VEGF165, mouse VEGF164, or hNT4, and 95 ml containing 5 3
104 Ba/F3-KDR, 2 3 104 Ba/F3-Flk-1, or Ba/F3-TrkB cells, respec-
tively, were added per well to a 96-well tissue culture plate. A total
of 5 ml serial dilutions of test protein in PBS/20% minimal Ba/F3 me-
dium was added to each well. After incubation for 72 hr at 37ºC, pro-
liferation was measured by the addition of 20 ml CellTiter 96 AQueous
One Solution Reagent (Promega) to each well, incubation for 4 hr at
37ºC, and measurement of the absorbance at 490 nm with a micro-
titer plate reader (Molecular Dynamics).
HUVEC cells (Human Umbilical Vein Endothelial Cells, Clonetics,
Walkersville, MD) from passages 2–6 were grown in EGM-2 medium
(Clonetics). A total of 5000 cells/well were resuspended in 200 ml
starvation medium (equal volumes of DMEM [GIBCO-BRL] and F-
12K medium [ATCC]), supplemented with 0.2% fetal bovine serum
and 13 penicillin/streptomycin/fungizone solution (GIBCO-BRL),
plated in 96-well tissue culture plates, and incubated for 48 hr. Bind-
ing proteins were added to the wells and incubated for 1 hr at 37º,
and then human VEGF165 was added to a final concentration of 16
ng/ml. After 48 hr, cell proliferation was measured by the addition
of 30 ml to each well of a mixture of 1.9 mg/ml CellTiter96 AQueous
MTS reagent (Promega) with 44 mg/ml phenazine methosulfate
(Sigma) and measurement of absorbance at 490 nm as described
above for Ba/F3 cells.
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